Effect of Oral Re-esterified Omega-3 Nutritional Supplementation on Dry Eyes
Epitropoulos AT, Donnenfeld ED, Shah ZA, Holland EJ, Gross M, Faulkner WJ, Matossian C, Lane SS, Toyos M, Bucci FA, Perry HD
Cornea · 84 citas
Etiquetas de revisión
Vínculos de autores con la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Autores
- Al menos un autor declara un vínculo económico con la industria
Según la declaración de financiación del texto completo.
Publicación
- Publicado
- 2016-07-21 · Cornea · vol. 35 · número 9 · págs. 1185–1191
- Editorial
- Lippincott Williams & Wilkins
- Citado
- 111 citas · más que el 99% de estudios similares · 13.6× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 49 trabajos
- Acceso
- Acceso abierto (revista híbrida) · CC-BY-NC-ND
- Áreas de investigación
- Ocular Surface and Contact Lens · Fatty Acid Research and Health · Retinal Diseases and Treatments
- Palabras clave
- dry eye, meibomian gland dysfunction, eicosapentaenoic acid, docosahexaenoic acid, omega-3 index, tear osmolarity, tear film break-up time, MMP-9, Ocular Surface Disease Index, linoleic acid, omega-3 supplementation, ocular surface
- MeSH
- meibomian glands, tears, humans, eyelid diseases, dry eye syndromes, fatty acids, omega-3, administration, oral, prospective studies, double-blind method, osmolar concentration, dietary supplements, adult, aged, aged, 80 and over, middle aged, female, male, matrix metalloproteinase 9, young adult
11 autores
- Alice Epitropoulos🇺🇸The Ohio State University Wexner Medical Center; Ophthalmic Consultants of Long Island; Minnesota Eye Consultants; Associated Eyecare; Bucci Laser Vision Institute; Cincinnati Eye Institute; Toyos Clinic; The Ohio State University
- Eric D. Donnenfeld🇺🇸The Ohio State University Wexner Medical Center; Bucci Laser Vision Institute; The Ohio State University
- Zubin A. Shah🇺🇸The Ohio State University Wexner Medical Center; The Ohio State University
- Edward J. Holland🇺🇸The Ohio State University Wexner Medical Center; The Ohio State University
- Michael Gross🇺🇸The Ohio State University Wexner Medical Center; The Ohio State University
- William J. Faulkner🇺🇸The Ohio State University Wexner Medical Center; The Ohio State University
- Cynthia Matossian🇺🇸The Ohio State University Wexner Medical Center; The Ohio State University
- Stephen S. Lane🇺🇸The Ohio State University Wexner Medical Center; The Ohio State University
- Melissa Morrison Toyos🇺🇸The Ohio State University Wexner Medical Center; The Ohio State University
- Frank A. Bucci🇺🇸The Ohio State University Wexner Medical Center; Bucci Laser Vision Institute; The Ohio State University
- Henry D. Perry🇺🇸The Ohio State University Wexner Medical Center; Bucci Laser Vision Institute; The Ohio State University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Purpose
To assess the effect of oral re-esterified omega-3 fatty acids on tear osmolarity, matrix metalloproteinase-9 (MMP-9), tear break-up time (TBUT), Ocular Surface Disease Index (OSDI), fluorescein corneal staining, Schirmer score, meibomian gland dysfunction (MGD) stage and omega-3 index in subjects with dry eyes and confirmed MGD.
Methods
This was a multicenter, prospective, interventional, placebo-controlled, double-masked study. Subjects were randomized to receive 4 softgels containing a total of 1680 mg of eicosapentaenoic acid/560 mg of docosahexaenoic acid or a control of 3136 mg of linoleic acid, daily for 12 weeks. Subjects were measured at baseline, week 6, and week 12 for tear osmolarity, TBUT, OSDI, fluorescein corneal staining, and Schirmer test with anesthesia. MMP-9 testing and omega-3 index were done at baseline and at 12 weeks.
Results
One hundred five subjects completed the study. They were randomized to omega-3 (n = 54) and control group (n = 51). Statistically significant reduction in tear osmolarity was observed in the omega-3 group versus control group at week 6 (-16.8 ± 2.6 vs. -9.0 ± 2.7 mOsm/L, P = 0.042) and week 12 (-19.4 ± 2.7 vs. -8.3 ± 2.8 mOsm/L, P = 0.004). At 12 weeks, a statistically significant increase in omega-3 index levels (P < 0.001) and TBUT (3.5 ± 0.5 s vs. 1.2 ± 0.5 s, P = 0.002) was also observed. Omega-3 group experienced a significant reduction in MMP-9 positivity versus control group (67.9% vs. 35.0%, P = 0.024) and OSDI scores decreased significantly in omega-3 (-17.0 ± 2.6) versus control group (-5.0 ± 2.7, P = 0.002).
Conclusions
Oral consumption of re-esterified omega-3 fatty acids is associated with statistically significant improvement in tear osmolarity, omega-3 index levels, TBUT, MMP-9, and OSDI symptom scores.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC-ND).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.